AC Immune reports Q1 EPS (19c) vs (18c) last year

Reports Q1 revenue $990k, consensus $323.67k. Dr. Andrea Pfeifer, CEO of AC Immune (ACIU) SA, commented: “AC Immune’s portfolio of active immunotherapies for precision prevention of neurodegeneration continues to advance in clinical development. Our interim Phase 2 data on ACI-7104.056, our wholly owned a-syn active immunotherapy, demonstrated strong immunogenicity and a favorable safety profile in early Parkinson’s disease patients, further supporting its best-in-class characteristics. Our two partnered active immunotherapy programs, ACI-24.060 and ACI-35.030, also advanced well in their respective ongoing Phase 2 trials. Furthermore, we highlighted progress with our promising early-stage assets in presentations of preclinical data at AD/PD(TM) 2025, including Morphomer(R) small molecule drugs targeting a-syn and Tau, and Morphomer-antibody drug conjugates our new class of drug candidates for neurodegenerative diseases.”